Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareRxFRA:29C1 66 EBITDA Margin % is 7.02% as of Jun. 2026, which is 538% above its 10-year median of 1.10. GuruFocus rates FRA:29C1 with a GF Score™ of 66/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review. Among 664 Healthcare Providers & Services companies, CareRx ranks worse than 58.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CareRx's EBITDA for the
three
months ended in Jun. 2026 was €4.1 Mil. CareRx's Revenue for the
three
months ended in Jun. 2026 was €57.9 Mil. Therefore, CareRx's EBITDA margin for the quarter that ended in Jun. 2026 was 7.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CareRx EBITDA Margin % Related Terms
CareRx EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CareRx's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:29C1 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, CareRx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareRx EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CareRx's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CareRx's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareRx (FRA:29C1) has a EBITDA Margin % of 7.02% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CareRx and its competitors. This is 538% above median its historical median of 1.10. According to the industry distribution chart, CareRx ranks #388 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 58.4%.
Is CareRx's EBITDA Margin % too high?
CareRx's current EBITDA Margin % of 7.02% is 538% above median its 10-year median of 1.10. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. CareRx's value of 7.02% is 31.2% below this industry median. Based on the distribution chart, CareRx ranks #388 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, CareRx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #388 out of 664 companies for EBITDA Margin %. This places CareRx in the lower half of its industry. The industry median EBITDA Margin % is 10.21. CareRx's value of 7.02% is 31.2% below this benchmark. While the company's 10-year median is 1.10 vs. the industry median of 10.21, CareRx has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareRx's current EBITDA Margin % of 7.02% is 31.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CareRx and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareRx's current EBITDA Margin % is 7.02%, which is 538% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current EBITDA Margin % of 7.02%. The stock's GF Value™ is €1.37, compared to a current price of €2.04 — trading 48.9% above its estimated fair value. The current EBITDA Margin % is 7.02%, which is 538% above median its 10-year median of 1.10 and 31.2% below the Healthcare Providers & Services industry median of 10.21. CareRx's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CareRx (FRA:29C1), the current EBITDA Margin % is 7.02% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareRx (FRA:29C1) Overvalued in 2026?
Based on GuruFocus' analysis, CareRx stock appears to be overvalued.
The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.
Key valuation signals for FRA:29C1:
EBITDA Margin %: 7.02% (538% above median its 10-year median of 1.10)
GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
Industry Position: 31.2% below the Healthcare Providers & Services median (#388 of 664)
No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score
Get the complete analysis for FRA:29C1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:29C1 has been successfully added to your 
